Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial

Banerjee, Sube; Hellier, Jennifer; Dewey, Michael; Romeo, Renée; Ballard, Clive; Baldwin, Robert C.; Bentham, Peter; Fox, Chris; Holmes, Clive; Katona, Cornelius; Knapp, Martín; Lawton, Claire; Lindesay, James; Livingston, Gill; McCrae, Niall; Moniz-Cook, Esmé; Murray, Joanna; Nurock, Shirley; Orrell, Martin; O’Brien, John T.; Poppe, Michaela; Thomas, Alan; Walwyn, Rebecca; Wilson, Kenneth; Burns, Alistair

doi:10.1016/s0140-6736(11)60830-1

Cited by 468 publications

(333 citation statements)

References 32 publications

Supporting

Mentioning

314

Contrasting

Unclassified

Order By: Relevance

“…HT reuptake inhibitors in AD shows limited efficacy (180). Where alterations in 5-HT transport may provide benefits in frontotemporal dementia, where the serotoninergic system is disrupted, although studies to date have showed that effects are limited to the noncognitive domains (181).…”

Section: Relevance To Alzheimer's Diseasementioning

confidence: 99%

Astrocytic transporters in Alzheimer's disease

Ugbode

Whalley

et al. 2017

Biochemical Journal

View full text Add to dashboard Cite

Astrocytes play a fundamental role in maintaining the health and function of the central nervous system. Increasing evidence indicates that astrocytes undergo both cellular and molecular changes at an early stage in neurological diseases, including Alzheimer's disease (AD). These changes may reflect a change from a neuroprotective to a neurotoxic phenotype. Given the lack of current disease-modifying therapies for AD, astrocytes have become an interesting and viable target for therapeutic intervention. The astrocyte transport system covers a diverse array of proteins involved in metabolic support, neurotransmission and synaptic architecture. Therefore, specific targeting of individual transporter families has the potential to suppress neurodegeneration, a characteristic hallmark of AD. A small number of the 400 transporter superfamilies are expressed in astrocytes, with evidence highlighting a fraction of these are implicated in AD. Here, we review the current evidence for six astrocytic transporter subfamilies involved in AD, as reported in both animal and human studies. This review confirms that astrocytes are indeed a viable target, highlights the complexities of studying astrocytes and provides future directives to exploit the potential of astrocytes in tackling AD.

show abstract

Section: Relevance To Alzheimer's Diseasementioning

confidence: 99%

Astrocytic transporters in Alzheimer's disease

Ugbode

Whalley

et al. 2017

Biochemical Journal

View full text Add to dashboard Cite

show abstract

“…Furthermore, one study showed no effect of SSRIs on depression in elderly patients with concurrent dementia (Banerjee et al, 2011).…”

Section: Recommended Treatment For Depressionmentioning

confidence: 99%

Depression and use of antidepressants in Swedish nursing homes: a 12-month follow-up study

Midlöv

Andersson

Östgren

et al. 2013

Int. Psychogeriatr.

View full text Add to dashboard Cite

show abstract

“…While the fi nding that survival of those with Alzheimer ' s dementia was not directly related to the consumption of antipsychotic or antidepressant medication is reassuring, this should not be interpreted as indicating a need for lowered vigilance and caution in the prescribing of these medications to people with Alzheimer ' s dementia. Evidence for effi cacy indicates modest or no benefi t for these treatments (Bains et al, 2002;Brodaty et al, 2003;Banerjee et al, 2011) and even if they are not directly associated with earlier death in this cohort, their potential to affect quality of life by causing side effects such as Parkinsonism or sedation, should not be overlooked.…”

Section: Prospective Cohort Studies In Dementiamentioning

confidence: 89%